01 octubre 2015

AMERICAN HEART JOURNAL. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement

Jan-Malte Sinning, MD, PhD, Kai C. Wollert, MD, PhDg, Alexander Sedaghat, MD, Christian Widera, MD, Marie-Caroline Radermacher, Claire Descoups, Christoph Hammerstingl, MD, PhD, Marcel Weber, MD, Anja Stundl, MD, Alexander Ghanem, MD, PhD, Julian Widder, MD, PhD, Mariuca Vasa-Nicotera, MD, PhD, Fritz Mellert, MD, PhD, Wolfgang Schiller, MD, Johann Bauersachs, MD, PhD, Berndt Zur, MD, PhD, Stefan Holdenrieder, MD, PhD, Armin Welz, MD, PhD, Eberhard Grube, MD, PhD, Michael J. Pencina, PhD, Georg Nickenig, MD, PhD, Nikos Werner, MD, PhDg, Tibor Kempf, MD, PhDg

Background: Up to 50% of the patients still die or have to be rehospitalized during the first year after transcatheter aortic valve replacement (TAVR). This emphasizes the need for more strategic patient selection. The aim of this prospective observational cohort study was to compare the prognostic value of risk scores and circulating biomarkers to predict all-cause mortality and rehospitalization in patients undergoing TAVR.

01 noviembre 2015

AMERICAN HEART JOURNAL. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience

Mauricio G. Cohen, MD, Ray Matthews, MD, Brij Maini, MD, Simon Dixon, MD, George Vetrovec, MD, David Wohns, MD, Igor Palacios, MD, Jeffrey Popma, MD, E. Magnus Ohman, MD, Theodore Schreiber, MD, William W. O’Neill, MD

Background: High-risk percutaneous coronary intervention (PCI) supported by percutaneous left ventricular assist devices offers a treatment option for patients with severe symptoms, complex and extensive coronary artery disease, and multiple comorbidities. The extrapolation from clinical trial to real-world practice has inherent uncertainties. We compared the characteristics, procedures, and outcomes of high-risk PCI supported by a microaxial pump (Impella 2.5) in a multicenter registry versus the randomized PROTECT II trial (NCT00562016).

01 noviembre 2015

AMERICAN HEART JOURNAL. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction

Jacob A. Doll, MD, Anne Hellkamp, MS, Laine Thomas, PhD, P. Michael Ho, MD, PhD, Michael C. Kontos, MD, Mary A. Whooley, MD, Thomas F. Boyden, MD, MS, Eric D. Peterson, MD, MPH, Tracy Y. Wang, MD, MHS, MSc

Background: Guidelines recommend cardiac rehabilitation after acute myocardial infarction, yet little is known about the impact of cardiac rehabilitation on medication adherence and clinical outcomes among contemporary older adults. The optimal number of cardiac rehabilitation sessions is not clear.

01 noviembre 2015

AMERICAN HEART JOURNAL. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Wei Ren Chen, MDa, Shun Ying Hu, MDa, Yun Dai Chen, MD, Ying Zhang, MSa, Geng Qian, MD, Jing Wang, MD, Jun Jie Yang, MD, Zhi Feng Wang, MS, Feng Tian, MD, Qing Xiu Ning, MS

Background: Several studies have shown that exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation myocardial infarction (STEMI). The effects of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients remain unclear. We planned to evaluate the effects of liraglutide on left ventricular function after primary percutaneous coronary intervention for STEMI.

01 noviembre 2015

AMERICAN HEART JOURNAL. Instantaneous Wave-Free Ratio versus Fractional Flow Reserve guided intervention (iFR-SWEDEHEART): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial

Matthias Götberg, MD, PhD, Evald H. Christiansen, MD, PhD, Ingibjörg Gudmundsdottir, MD, PhD, Lennart Sandhall, MD, Elmir Omerovic, MD, PhD, Stefan K. James, MD, PhD, David Erlinge, MD, PhD, Ole Fröbert, MD, PhD

Background: Instantaneous wave-free ratio (iFR) is a new hemodynamic resting index for assessment of coronary artery stenosis severity. iFR uses high frequency sampling to calculate a gradient across a coronary lesion during a period of diastole. The index has been tested against fractional flow reserve (FFR) and found to have an overall classification agreement of 80% to 85%. Whether the level of disagreement is clinically relevant is unknown. Clinical outcome data on iFR are scarce. This study is a registry-based randomized clinical trial, which is a novel strategy using health quality registries as on-line platforms for randomization, case record forms, and follow-up.

01 diciembre 2015

AMERICAN HEART JOURNAL. Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation (WISE)

Wilmer W. Nichols, PhD, Scott J. Denardo, MD, Jonathan B. Davidson, MD, Tianyao Huo, MS, C. Noel Bairey Merz, MD, Carl J. Pepine, MD

Background: Increased aortic stiffness and reduced coronary flow reserve (CFR) independently predict adverse outcomes. But information about relationships between arterial properties and CFR in subjects without obstructive coronary artery disease (CAD) is limited.

01 diciembre 2015

AMERICAN HEART JOURNAL. Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan

Thomas F. Boyden, MD, MS, Karen E. Joynt, MD, MPH, Lisa McCoy, MS, Megan L. Neely, PhD, Matthew A. Cavender, MD, MPH, Simon Dixon, MD, Frederick A. Masoudi, MD, MSPH, Eric Peterson, MD, MPH, Sunil V. Rao, MD, Hitinder S. Gurm, MD

Introduction: Public reporting (PR) is a policy mechanism that may improve clinical outcomes for percutaneous coronary intervention (PCI). However, prior studies have shown that PR may have an adverse impact on patient selection. It is unclear whether alternatives to PR, such as collaborative quality improvement (CQI), may drive improvements in quality of care and outcomes for patients receiving PCI without the unintended consequences seen with PR.

01 diciembre 2015

AMERICAN HEART JOURNAL. Clinical characteristics and in hospital outcomes of heart transplant recipients with allograft vasculopathy undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry

Tarun W. Dasari, MD, MPH, Jorge F. Saucedo, MD, Selim Krim, MD, Mohamad Alkhouli, MD, Gregg C. Fonarow, MD, Rene Alvarez, MD, Homam Ibrahim, MD, David Dai, PhD, Tracy Y. Wang, MD, MHS, MSc, Marco Costa, MD, JoAnn Lindenfeld, MD, John C. Messenger, MD

Background: Cardiac allograft vasculopathy is a major cause of morbidity and mortality following heart transplantation. Large multicenter studies evaluating the clinical characteristics and inhospital outcomes of heart transplant recipients undergoing percutaneous coronary intervention (PCI) are lacking.

01 diciembre 2015

AMERICAN HEART JOURNAL. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database–Keio interhospital Cardiovascular Studies (JCD-KiCS)

Shun Kohsaka, MD, PhD, Hiroaki Miyata, PhD, Ikuko Ueda, PhD, Frederick A. Masoudi, MD, MSPH, Eric D. Peterson, MD, MPH, Yuichiro Maekawa, MD, Akio Kawamura, MD, Keiichi Fukuda, MD, PhD, Matthew T. Roe, MD, MHS, John S. Rumsfeld, MD, PhD on behalf of the JCD-KiCS and NCDR

Background: Details on Japanese patients undergoing percutaneous coronary intervention (PCI) and how they compare to US patients remain unclear. Furthermore, the application of US risk models has not been evaluated internationally.

01 diciembre 2015

AMERICAN HEART JOURNAL. Paradigm shift in the intervention for secundum atrial septal defect in an era of transcatheter closure: A national birth cohort study

Mei-Hwan Wu, MD, PhD, Hui-Chi Chen, PhD, Jou-Kou Wang, MD, PhD, Feng-Yu Kao, MS, San-Kuei Huang, MD

Background: Secundum atrial septal defect (ASDII) is a common congenital heart defect, but the intervention, either transcatheter or surgical, needs are unclear. This study was to examine the paradigm shift in its intervention in an era of transcatheter closure.

01 noviembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. “A bend in time”: Shaping the sheath facilitates left atrial appendage closure

Sameer Gafoor MD1,2, Luisa Heuer BA1, Philipp Schulz BA1, Predrag Matic MD1, Jennifer Franke MD1,3, Stefan Bertog MD1,4, Markus Reinartz MD1, Laura Vaskelyte MD1, Ilona Hofmann MD1 andHorst Sievert MD1,*

Objectives: The purpose of this study is to determine feasibility, safety, and effectiveness of the “shape-the-sheath” method in left atrial appendage closure.

01 noviembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Outcomes of transcatheter aortic valve replacement in patients with chronic liver disease

Anoop M. Shah MD1,†, Jeffrey Ogbara MD1,†, Howard C. Herrmann MD1, Zachary Fox BA2, Mitul Kadakia MD1, Saif Anwaruddin MD1, Joseph E. Bavaria MD2, Nimesh D. Desai MD2, Dinesh Jagasia MD1, Wilson Y. Szeto MD2, Robert H. Li MD1, Prashanth Vallabhajosyula MD2 andJay Giri MD, MPH1,*

Objective: Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to high-risk surgery in patients with comorbid conditions. The role of TAVR in patients with liver disease has not been examined.

01 noviembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Transcarotid balloon valvuloplasty in neonates and small infants with critical aortic valve stenosis utilizing continuous transesophageal echocardiographic guidance: A 22 year single center experience from the cath lab to the bedside

Sunil Patel MD, Ashish P. Saini MD, Athira Nair MD andHoward S. Weber MD*

Objective: Utilization of continuous transesophageal echocardiographic guidance (cTEE) during transcarotid balloon valvuloplasty (TCBV) in neonates and small infants with critical aortic valve stenosis (AS) allows for continuous hemodynamic assessment and improved outcomes.

01 noviembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Balloon valvuloplasty for congenital aortic stenosis: Multi-center safety and efficacy outcome assessment

Alejandro Torres MD1, Julie A. Vincent MD1, Allen Everett MD2, Scott Lim MD3, Susan R. Foerster MD4, Audrey C. Marshall MD5, Robert H. Beekman III MD6, Joshua Murphy MD7, Sara M. Trucco MD8, Kimberlee Gauvreau MD5, Ralf Holzer MD, MSc9, Lisa Bergersen MD, MPH5 andDiego Porras MD5,*

Objective: To describe contemporary outcomes of balloon aortic valvuloplasty (BAVP) performed in 22 US centers. Background: BAVP constitutes first-line therapy for congenital aortic stenosis (cAS) in many centers.

15 noviembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study

Gregory J. Wilson MD1,*, Angela Marks BSC2, Kimberly J. Berg BSC2, Michael Eppihimer PhD2, Natalia Sushkova MD2, Steve P. Hawley MSC1, Kimberly A. Robertson BSC2, David Knapp PhD2, Douglas E. Pennington PhD2, Yen-Lane Chen PhD2, Aaron Foss PhD2, Barbara Huibregtse DVM2 andKeith D. Dawkins MD2

Aims: SYNERGY is a novel platinum chromium alloy stent that delivers abluminal everolimus from an ultrathin poly-lactide-co-glycide (PLGA) biodegradable polymer. This study evaluated the in vivo degradation of the polymer coating, everolimus release time course, and vascular compatibility of the SYNERGY stent.